After a conference call in which the medical device giant revealed an expanded use of metal 3D printing, Stryker has created actually additional progress in delivering 3D printed implants to market. The company has only revealed 510(k) clearance of the FDA for their Tritanium PL Posterior Lumbar Cage, a device aimed at encouraging spinal fixation in patients with degenerative disc disease.
Stryker’s Tritanium is mentioned as a porous titanium material created for improved bone growth, necessary for securing a spinal implant in place over time. This patented material is essential for the company’s Tritanium PL Posterior Lumbar Cage, utilized to treat degenerative disc disease, grade I spondylolisthesis and degenerative scoliosis. Because the device is 3D printed, Stryker is able-bodied to contribute the lumbar cage in a variety of widths, lengths, heights, and lordotic angles. And, through the use of sizeable lateral windows and an open architecture, fusion of the cage with the body can be observed in CT scans and X-rays. And increased surface area, achieved through serrations inside the cage, allow for bidirectional fixation.
Brad Paddock, President of the Spine Division at Stryker, says of the product, “This is an amazing time for Stryker. We are committed to contributeing a full range of new spinal products which allow surgeons to assist their patients return to a additional active lifestyle. Our high end 3D additive making capabilities allow us to exactly make the porous structures of Tritanium and specific implant geometries. We are jubilant to bring this innovation to our spine surgeon community and their patients.”
The device can be created on the market-bodied to orthopaedic and neurosurgeons in the 2nd quarter of 2016. This, along with news of Materialise of its new inPrint software and the ongoing clinical trial of 3D printed pre-surgical models, suggests which 2016 may only be the year which 3D printing becomes mainstream in the medical field.